Paper Titles in Periodical
International Letters of Chemistry, Physics and Astronomy
Volume 30

Subscribe

Subscribe to our Newsletter and get informed about new publication regulary and special discounts for subscribers!

ILCPA > Volume 30 > Study of Anticoagulant Dabigatran by Analytical...
< Back to Volume

Study of Anticoagulant Dabigatran by Analytical Instrumentation

Full Text PDF

Abstract:

Dabigatran with IUPAC name 3-({2-[(4-Carbamimidoyl-phenylamino)-methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}-pyridin-2-yl-amino)-propionic acid, which can be used to prevent strokes in those with atrial fibrillation due to causes other than heart valve disease, and at least one additional risk factor for stroke (congestive heart failure, hypertension, age, diabetes, and prior stroke), with molecular formula C34H41N7H5 was studied in detail for functional group analysis with FTIR, characteristic absorbance by UV-NIR, thermal behavior by TGA-DTA-DSC, particle size and stability of the molecule with Nano particle size analyzer. The structure was confirmed by LC-MS/MS with ESI probe and mass was found in aggregation with the reported standard values. The purity of drug was determined by Prep. HPLC analysis. FTIR analysis showed the characteristic peak of carboxylic acid, UV-NIR analysis showed that the λmax was 224 nm with methanol as a diluent, the compound was found stable in the thermal analysis, the average particle size was found to be 25.2 nm, Z-average as 0.2 nm and zeta potential as -67.6 mv hence showed excellent stability in the zeta potential analysis as per ASTM standards D4187-82, American Society of Testing and Materials, 1985.

Info:

Periodical:
International Letters of Chemistry, Physics and Astronomy (Volume 30)
Pages:
233-242
Citation:
B. Patel et al., "Study of Anticoagulant Dabigatran by Analytical Instrumentation", International Letters of Chemistry, Physics and Astronomy, Vol. 30, pp. 233-242, 2014
Online since:
March 2014
Export:
Distribution:
References:

Pradaxa Official FDA information, side effects and uses. Drugs. com (2012).

Hanley J. P., J. Clin. Pathol. 57(11) (2004) 1132-1139.

Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience". Prescrire Int 22(139) (2013) 155-159.

Pradaxa Official FDA information, side effects and uses,. Drugs. com. (2012).

Aguilar M., Hart R., Antiplatelet therapy for preventing stroke in patients with non- valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks,. Cochrane Database Syst Rev (2005).

Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients,. Prescrire Int 21 (124) (2012) 3336.

Adam SS, McDuffie JR, Ortel TL, Williams JW., Ann. Intern. Med. 157(11) (2012) 796-807.

Pradaxa,. European Medicines Agency (2012).

Khokhani K, Khatri T, Ram V, Patel P., Chemistry & Biology Interface 3(3) (2013) 192-200.

Ram VR, Dave PN, Joshi HS., Journal of Chromatographic Science 50 (8) (2012) 721-726.

Bhogayta J., Khatri T., Ram V., Dave P., International Letters of Chemistry, Physics and Astronomy 10 (2014) 1-13.

Show More Hide